The Combination of Insulin-Like Growth Factor Receptor 1 (IGF1R) Antibody Cixutumumab and Mitotane as a First-Line Therapy for Patients with Recurrent/Metastatic Adrenocortical Carcinoma: a Multi-institutional NCI-Sponsored Trial

MLA

Francis P. Worden, et al. “The Combination of Insulin-Like Growth Factor Receptor 1 (IGF1R) Antibody Cixutumumab and Mitotane as a First-Line Therapy for Patients with Recurrent/Metastatic Adrenocortical Carcinoma: A Multi-Institutional NCI-Sponsored Trial.” Hormones and Cancer, vol. 5, May 2014, pp. 232–39. EBSCOhost, https://doi.org/10.1007/s12672-014-0182-1.

APA

Francis P. Worden, Gary D. Hammer, Krishna Rao, Carole A. Ramm, Manisha H. Shah, Edem Agamah, Tobias Else, Antonio M. Lerario, Elizabeth Hesseltine, & Walter M. Stadler. (2014). The Combination of Insulin-Like Growth Factor Receptor 1 (IGF1R) Antibody Cixutumumab and Mitotane as a First-Line Therapy for Patients with Recurrent/Metastatic Adrenocortical Carcinoma: a Multi-institutional NCI-Sponsored Trial. Hormones and Cancer, 5, 232–239. https://doi.org/10.1007/s12672-014-0182-1

Chicago

Francis P. Worden, Gary D. Hammer, Krishna Rao, Carole A. Ramm, Manisha H. Shah, Edem Agamah, Tobias Else, Antonio M. Lerario, Elizabeth Hesseltine, and Walter M. Stadler. 2014. “The Combination of Insulin-Like Growth Factor Receptor 1 (IGF1R) Antibody Cixutumumab and Mitotane as a First-Line Therapy for Patients with Recurrent/Metastatic Adrenocortical Carcinoma: A Multi-Institutional NCI-Sponsored Trial.” Hormones and Cancer 5 (May): 232–39. doi:10.1007/s12672-014-0182-1.